Evidence map›Paper›PMID 33726485›Full record

ArticleTurkish journal of medical sciences2021

Which hematological markers have predictive value as early indicators of severe COVID-19 cases in the emergency department?

İshak Şan, Emin Gemcioğlu, Mehmet Davutoğlu, Ramis Çatalbaş, Berkan Karabuğa, Enes Kaptan, Abdulsamet Erden, Orhan Küçükşahin, İhsan Ateş, Selma Karaahmetoğlu and 6 more

Abstract read
In one paragraph

Article in Turkish journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

İshak ŞanDepartment of Emergency, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Emin GemcioğluDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
Mehmet DavutoğluDepartment of Internal Medicine, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Ramis ÇatalbaşDepartment of Internal Medicine, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Berkan KarabuğaDepartment of Internal Medicine, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Enes KaptanDepartment of Internal Medicine, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Abdulsamet ErdenDivision of Rheumatology, Department of Internal Medicine,Ankara City Hospital, Ankara, Turkey.
Orhan KüçükşahinDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
İhsan AteşDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
Selma KaraahmetoğluDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
İmran HasanoğluDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Osman İnanDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
Büşra Nur ÜnalDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
Ecem ErdemirDepartment of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
Fatih Ahmet KahramanDepartment of Emergency, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
Rahmet GünerDepartment of Emergency, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Coronavirus 2019 disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a pandemic infectious disease that causes morbidity and mortality. As a result of high mortality rate among the severe COVID-19 patients, the early detection of the disease stage and early effective interventions are very important in reducing mortality. Hence, it is important to differentiate severe and nonsevere cases from each other. To date, there are no proven diagnostic or prognostic parameters that can be used in this manner. Due to the expensive and not easily accessible tests that are performed for COVID-19, researchers are investigating some parameters that can be easily used. In some recent studies, hematological parameters have been evaluated to see if they can be used as predictive parameters. Materials and methods: In the current study, almost all hematological parameters were used, including the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, monocyte/lymphocyte ratio, mean platelet volume to lymphocyte ratio, mean platelet volume to platelet ratio, plateletcrit, and D-dimer/fibrinogen ratio, neutrophil/lymphocyte/platelet scoring system, and systemic immune-inflammation index. A total of 750 patients, who were admitted to Ankara City Hospital due to COVID-19, were evaluated in this study. The patients were classified into 2 groups according to their diagnosis (confirmed or probable) and into 2 groups according to the stage of the disease (nonsevere or severe). Results: The values of the combinations of inflammatory markers and other hematological parameters in all of the patients with severe COVID-19 were calculated, and the predicted values of these parameters were compared. According to results of the study, nearly all of the hematological parameters could be used as potential diagnostic biomarkers for subsequent analysis, because the area under the curve (AUC) was higher than 0.50, especially for the DFR and NLR, which had the highest AUC among the parameters. Conclusion: Our findings indicate that, the parameters those enhanced from complete blood count, which is a simple laboratory test, can help to identify and classify COVID-19 patients into non-severe to severe groups.

Indexed as

AdultAgedAged, 80 and overBiomarkersCOVID-19COVID-19 TestingEmergency Service, HospitalFemaleHematologic TestsHemoglobinsHumansLymphocytesMaleMiddle AgedNeutrophilsPredictive Value of TestsBiomarkersHemoglobinsCOVID-19hematological testspredictive values of testsSARS-CoV-2

Identifiers

PMID33726485
PMCPMC10734829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.